体内研究 (In Vivo) |
Bartogenic acid (3 mg/kg;静脉注射;每日一次;共 21 天) 可使 SCID 小鼠体内 SKOV-3 卵巢肿瘤的生长抑制 41.47%。 Bartogenic acid (1-4 mg/kg;口服/局部给药;每日;13.5 周) 对 DMBA (MS-Y05966)/巴豆油诱导的 Swiss albino 小鼠皮肤癌具有剂量依赖性化学预防作用,其中 4 mg/kg 口服剂量组的肿瘤发生率最低 (36.1%),且抗氧化标志物水平和皮肤结构接近正常。 Bartogenic acid (2-10 mg/kg;口服;每日一次,共 21 天) 可保护大鼠免受 CFA (MS-E83942) 诱导的原发性和继发性关节炎损伤、体重变化和血液学紊乱。
| Animal Model: |
SCID (female, 5 weeks old, subcutaneous inoculation of SKOV-3 cells to establish a xenograft model) |
| Dosage: |
3 mg/kg |
| Administration: |
i.v.; daily; 21 days |
| Result: |
Achieved 41.47% tumor growth inhibition (p < 0.001) compared to vehicle controls, with mean tumor volume of 364.70 mm3 on day 21. Showed no significant reduction in NF-κB H score, viable tumor cell score, fibrosis score, TGF-β1 levels, or MMP9 levels, but significantly increased necrosis score (p < 0.05).
|
| Animal Model: |
Swiss albino (6-8 weeks old, 23-25 gm, DMBA/Croton oil-induced two-stage skin carcinogenesis) |
| Dosage: |
1 mg/kg; 2 mg/kg; 4 mg/kg |
| Administration: |
p.o.; daily; 13.5 weeks; topical; daily; 13.5 weeks |
| Result: |
Reduced tumor incidence to 89.3%, with an average of 9.72 tumors per tumor-bearing mouse, mean tumor volume of 124.8 mm3, and mean tumor weight of 1.01 gm at 1 mg/kg oral dose. Partially restored glutathione (GSH) content and activities of catalase, superoxide dismutase (SOD), and glutathione peroxidase (GSHPx), with mild histopathological improvement at 1 mg/kg oral dose. Reduced tumor incidence to 52.4%, with an average of 6.34 tumors per tumor-bearing mouse, mean tumor volume of 89.7 mm3, and mean tumor weight of 0.61 gm at 2 mg/kg oral dose. Significantly reduced skin malondialdehyde (MDA) levels to 125.7 μg/mg protein, restored GSH content to near-normal levels, significantly increased catalase, SOD, and GSHPx activities, and preserved normal skin architecture with only mild epidermal cell invasion at 2 mg/kg oral dose. Reduced tumor incidence to 36.1%, with an average of 4.19 tumors per tumor-bearing mouse, mean tumor volume of 45.6 mm3, and mean tumor weight of 0.11 gm at 4 mg/kg oral dose. Significantly reduced skin MDA levels to 104.5 μg/mg protein, restored GSH content and catalase, SOD, and GSHPx activities to near-normal levels, and preserved fully normal skin architecture with no epidermal thickening or cell invasion at 4 mg/kg oral dose. Reduced tumor incidence to 48.2%, with an average of 8.21 tumors per tumor-bearing mouse, mean tumor volume of 63.5 mm3, and mean tumor weight of 0.51 gm at 4 mg/kg topical dose. Reduced skin MDA levels to 141.6 μg/mg protein, restored GSH content and catalase, SOD, and GSHPx activities to near-normal levels, and showed mild to moderate histopathological improvement at 4 mg/kg topical dose. |
| Animal Model: |
Wistar rats (either sex, 100-150 g, Complete Freund’s Adjuvant-induced arthritis) |
| Dosage: |
2 mg/kg; 5 mg/kg; 10 mg/kg |
| Administration: |
p.o.; daily; 21 days |
| Result: |
Reduced primary arthritic lesions to 113% rise in injected paw volume and secondary lesions to 15% rise in non-injected paw volume at 2 mg/kg, 109% rise and 12% rise at 5 mg/kg, and 91% rise and 11% rise at 10 mg/kg (all P <.01). Resulted in 37 g body weight gain at 2 mg/kg, 36 g gain at 5 mg/kg, and 39 g gain at 10 mg/kg (all P <.01). Reduced thymus weight to 0.12 g and spleen weight to 0.96 g at 2 mg/kg, 0.12 g and 0.84 g at 5 mg/kg, and 0.085 g and 0.74 g at 10 mg/kg (all thymus weights and 5 mg/kg, 10 mg/kg spleen weights P <.05 or P <.01). Reduced WBC count to 7.5 ×103/mm3, ESR to 12 mm/h, CRP to 4.4 mg/dL, and RF to 37 IU/mL at 2 mg/kg; increased RBC count to 9 ×106/mm3, reduced WBC count to 7.2 ×103/mm3, increased Hb to 15 mg%, reduced CRP to 2.2 mg/dL, and RF to 33 IU/mL at 5 mg/kg; increased RBC count to 9.8 ×106/mm3, reduced WBC count to 5.6 ×103/mm3, reduced ESR to 11 mm/h, increased Hb to 16 mg%, reduced CRP to 1.4 mg/dL, and RF to 23 IU/mL at 10 mg/kg (all significant vs control, P <.01). Reduced arthritis score to median 6 (4, 8), flexion pain test score to median 1.5 (1, 2), mobility score to median 1.5 (1, 2), and improved stance score to median 3 (2, 3) at 10 mg/kg (P <.05 or P <.01); 2 mg/kg and 5 mg/kg showed non-significant pain score improvements. Protected against soft tissue swelling, periarticular bone resorption, bone erosion, and joint space narrowing in the adjuvant-injected paw at 10 mg/kg. |
|